CRDA: Hepatic Outcomes (2023)

CRDA: Hepatic Outcomes (2023)

• Intervention
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on alanine transaminase?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on alanine transaminase in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Low (C)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on alanine transaminase?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
      • Ryan M, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond P, Johnson N, Wilson A. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology 2013; 59:138-143
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on aspartate aminotransferase?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on aspartate aminotransferase in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Low (C)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on aspartate aminotransferase?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on gamma-glutamyl transferase?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on gamma-glutamyl transferase (GGT) in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Very Low (D)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on gamma-glutamyl transferase?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Abete I, Cantero I, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M,T ur J, Martinez J, Zulet M. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019; 11:
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
      • Ryan M, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond P, Johnson N, Wilson A. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology 2013; 59:138-143
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on hepatic steatosis?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on hepatic steatosis in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Very Low (D)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on hepatic steatosis?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on liver fat?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on liver fat in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Grade: Low (C)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on liver fat?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
      • Ryan M, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond P, Johnson N, Wilson A. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology 2013; 59:138-143
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023
     
  In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on liver stiffness?

  • Conclusion

    Evidence suggests that intake of a moderate-carbohydrate (CHO) diet compared to a higher CHO intake may have no effect on liver stiffness in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). 

  • Grade: Very Low (D)
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), what is the effect of carbohydrate (CHO) restriction compared to higher CHO diets on liver stiffness?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Abbate M, Mascaró C, Montemayor S, Barbería-Latasa M, Casares M, Gómez C, Angullo-Martinez E, Tejada S, Abete I, Zulet M, Sureda A, Martínez J, Tur J. Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients 2021; 13:
      • Marin-Alejandre B, Cantero I, Perez-Diaz-Del-Campo N, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M, Tur J, Martinez J, Abete I, Zulet M. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International 2021; 41:1532-1544
      • Properzi C, O'Sullivan T, Sherriff J, Ching H, Jeffrey G, Buckley R, Tibballs J, MacQuillan G, Garas G, Adams L. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology (Baltimore, MD) 2018; 68:1741-1754
  • Search Plan and Results: CRDA: Overweight or Obesity and MASLD 2023